DexCom, Inc.

Stage 2 · Advancing · week 17

As of Oct 22, 2026, DexCom is in Stage 2, the uptrend phase, now in week 17 (since Jun 29, 2026). It closed at $78.32, 15.2% below its 52-week high and above its 200-day average, which is rising.

$78.32

-2.79% today

$29.6B · Large cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care

Is DXCM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 21w

S4 17w

S1 17w

S4 16w

S2 17w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 3w → S4 11w → S1 6w → S2 21w → S3 7w → S4 17w → S1 17w → S2 1w → S3 2w → S4 8w → S1 1w → S2 9w → S3 6w → S4 16w → S1 11w → S4 10w → S1 3w → S2 17w current

Total tracked: 165 weeks across 19 stage runs.

DXCM among Medical Devices36th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…36	DXCMDexCom, Inc.	Stage 2 · wk 17	64	−10.7%

vs 52W High

-15.2%

$54.84 lo$92.34 hi

15.2% below 52W high, deeper pullback

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 17

1w13w26w

Week 17, proven structure

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

5.5%

200 DMA: $74.27 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

2.75x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-10.7%

+9.5%

+24.9%

YTD

+17.7%

+12.3%

Scan Membership

Breakout Watch

Latest: 2025-06-09

10 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 17 · Vol 2.75x

2026-10-21S2

Wk 17 · Vol 1.74x

2026-10-20S2

Wk 16 · Vol 0.60x

2026-10-19S2

Wk 16 · Vol 0.64x

2026-10-16S2

Wk 16 · Vol 0.88x

2026-10-15S2

Wk 16 · Vol 1.17x

2026-10-14S2

Wk 16 · Vol 0.84x

2026-10-13S2

Wk 15 · Vol 0.95x

2026-10-12S2

Wk 15 · Vol 0.68x

2026-10-09S2

Wk 15 · Vol 0.70x

2026-10-08S2

Wk 15 · Vol 0.80x

2026-10-07S2

Wk 15 · Vol 0.63x

Moving averages & range

50 DMA

$87.10

200 DMA

$74.27

52W High

$92.34

52W Low

$54.84

5D Low

$78.32

Resistance levels (recent highs)

20d High

$87.71

60d High

$92.34

120d High

$92.34

250d High

$92.34

Next resistance

+12.0%

to 20d High

P/E (TTM)

31.1

Forward 25.1

Earnings Growth (YoY)

+43.6%

Revenue +13.1%

ROE

+38.5%

Profit margin +20.1%

Dividend Yield

0.00%

P/B 11.3

DexCom: quick answers

What stage is DexCom in?

As of Oct 22, 2026, DexCom (DXCM) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 29, 2026 and is in week 17. What the four stages mean

Is DexCom in an uptrend?

Yes. DexCom is in a Stage 2 uptrend. It trades 5.5% above its 200-day average, which is rising.

How far is DexCom from its 52-week high?

DexCom closed at $78.32 on Oct 22, 2026, 15.2% below its 52-week high of $92.34. Its 52-week low is $54.84.

How has DexCom performed over the past year?

As of Oct 22, 2026, DexCom is up 12.3% over the past year and up 17.7% so far in 2026.

Which sector and industry is DexCom in?

DexCom is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.